Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Malgorzata Smola1,2, Thierry Vandamme1, Adam Sokolowski21Universit&eacute; Louis Pasteur, Facult&eacute; de Pharmacie, D&eacute;partement de Chimie Bioorganique, Illkirch Graffenstaden, France; 2Wroclaw University of Technology, Faculty of Chemical Engineering, Wroclaw, Polan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Malgorzata Smola, Thierry Vandamme, Adam Sokolowski
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/792e01a597ca4d1490801efdfcc66029
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:792e01a597ca4d1490801efdfcc66029
record_format	dspace
spelling	oai:doaj.org-article:792e01a597ca4d1490801efdfcc660292021-12-02T02:44:05ZNanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases1176-91141178-2013https://doaj.org/article/792e01a597ca4d1490801efdfcc660292008-03-01T00:00:00Zhttp://www.dovepress.com/nanocarriers-as-pulmonary-drug-delivery-systems-to-treat-and-to-diagno-a742https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Malgorzata Smola1,2, Thierry Vandamme1, Adam Sokolowski21Universit&eacute; Louis Pasteur, Facult&eacute; de Pharmacie, D&eacute;partement de Chimie Bioorganique, Illkirch Graffenstaden, France; 2Wroclaw University of Technology, Faculty of Chemical Engineering, Wroclaw, PolandAbstract: The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.Keywords: nanotechnology, nanocarriers, nanoparticle, liposome, lung, pulmonary drug delivery, drug targeting, respiratory disease, microemulsion, bioavailability, micelle Malgorzata SmolaThierry VandammeAdam SokolowskiDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2008, Iss Issue 1, Pp 1-19 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Malgorzata Smola Thierry Vandamme Adam Sokolowski Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
description	Malgorzata Smola1,2, Thierry Vandamme1, Adam Sokolowski21Universit&eacute; Louis Pasteur, Facult&eacute; de Pharmacie, D&eacute;partement de Chimie Bioorganique, Illkirch Graffenstaden, France; 2Wroclaw University of Technology, Faculty of Chemical Engineering, Wroclaw, PolandAbstract: The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.Keywords: nanotechnology, nanocarriers, nanoparticle, liposome, lung, pulmonary drug delivery, drug targeting, respiratory disease, microemulsion, bioavailability, micelle
format	article
author	Malgorzata Smola Thierry Vandamme Adam Sokolowski
author_facet	Malgorzata Smola Thierry Vandamme Adam Sokolowski
author_sort	Malgorzata Smola
title	Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
title_short	Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
title_full	Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
title_fullStr	Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
title_full_unstemmed	Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
title_sort	nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/792e01a597ca4d1490801efdfcc66029
work_keys_str_mv	AT malgorzatasmola nanocarriersaspulmonarydrugdeliverysystemstotreatandtodiagnoserespiratoryandnonrespiratorydiseases AT thierryvandamme nanocarriersaspulmonarydrugdeliverysystemstotreatandtodiagnoserespiratoryandnonrespiratorydiseases AT adamsokolowski nanocarriersaspulmonarydrugdeliverysystemstotreatandtodiagnoserespiratoryandnonrespiratorydiseases
_version_	1718402170211008512

Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases

Ejemplares similares